DiaMedica Therapeutics DMAC
NASDAQ DMAC
$8.25 -0.10 (-1.20%)
As of: Oct 2, 2026 · 1:18 PM EDT

DiaMedica Therapeutics (DMAC) Return on Sales [ROS] (2018)

Updated

DiaMedica Therapeutics (DMAC) recorded Return on Sales [ROS] of -1352.20% in FY2018.

Analysis

DiaMedica Therapeutics (DMAC) Return on Sales [ROS] (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn 28.21%
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn 37.86%
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -3.52%
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn 32.97%
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn 20.57%
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn 34.95%
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -133.21%
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn 28.37%
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn 37.40%
10 DiaMedica Therapeutics 445.97 Mn 445.97 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 -297.40%
API Access

DiaMedica Therapeutics Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=DMAC&period=max&api_key=YOUR_API_KEY